{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:03:33Z","timestamp":1772892213806,"version":"3.50.1"},"reference-count":0,"publisher":"Canadian Urological Association Journal","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CUAJ"],"abstract":"<jats:p>Introduction: Interstitial cystitis\/bladder pain syndrome (IC\/BPS) patients represent a heterogeneous group with pain and urinary storage symptoms and varying responses to current treatment options. The novel beta-3 agonist, mirabegron, has been shown to improve storage symptoms of patients with bladder overactivity; however, its effect on symptoms in the IC\/BPS population has yet to be studied.Methods: Patients diagnosed at a single IC centre with IC\/BPS undergoing standard therapy were treated with additional daily mirabegron 25 mg and seen in followup post-treatment. Patients completed the Interstitial Cystitis Symptom Index and Problem Index (ICSI\/ICPI), and the Pelvic Pain and Urgency\/Frequency Patient Symptom Scale (PUF) prior to and following mirabegron treatment. Global (NRS) and symptom-specific outcomes were assessed by comparing the pre- and post-treatment mean scores using tailed-t test (p&lt;0.05 considered statistically significant).Results: A total of 23 patients were available for review pre- and post-mirabegron treatment. There was no significant difference in ICSI (p=0.448), ICPI (p=0.352), or PUF (p=0.869) pre- and post-treatment. Analysis of symptom-specific outcomes show statistically significant improvements in urgency (p=0.048); however, no statistically significant improvements in frequency (p=0.951) or pain (p=0.952) were observed with mirabegron therapy.Conclusions: IC\/BPS patients treated with mirabegron had improvement of urinary urgency, but no significant benefit in terms of pain or urinary frequency. This data suggests that mirabegron\u2019s role in the IC\/BPS patient should be that of adjuvant treatment to ameliorate urgency.<\/jats:p>","DOI":"10.5489\/cuaj.4325","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T14:56:21Z","timestamp":1513436181000},"page":"E100-4","source":"Crossref","is-referenced-by-count":8,"title":["Mirabegron as adjuvant treatment for patients with interstitial cystitis\/bladder pain syndrome"],"prefix":"10.5489","volume":"12","author":[{"given":"Michael","family":"Di Lena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Tolls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri-Lynn","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Curtis","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3456","published-online":{"date-parts":[[2017,12,16]]},"container-title":["Canadian Urological Association Journal"],"original-title":[],"link":[{"URL":"https:\/\/cuaj.ca\/index.php\/journal\/article\/download\/4325\/3533","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cuaj.ca\/index.php\/journal\/article\/download\/4325\/3421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T06:22:33Z","timestamp":1562739753000},"score":1,"resource":{"primary":{"URL":"https:\/\/cuaj.ca\/index.php\/journal\/article\/view\/4325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,16]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,12,16]]}},"URL":"https:\/\/doi.org\/10.5489\/cuaj.4325","relation":{},"ISSN":["1920-1214","1911-6470"],"issn-type":[{"value":"1920-1214","type":"electronic"},{"value":"1911-6470","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,16]]}}}